Key result
Emerging LDL-C lowering agents address residual ASCVD risk in patients not reaching targets on statins.
Why the study?
Many patients do not attain target LDL-C on statins or remain at considerable ASCVD risk, highlighting the need for more aggressive LDL-C-lowering therapies.
This review discusses emerging LDL-C lowering therapies, including inhibitors of ATP-citrate lyase, PCSK9, ANGPTL3, and CETP, to address residual ASCVD risk in patients not reaching targets with statins.
Answers are grounded in this paper and cite their sources.
Should not yet change statin-first practice for residual risk; leaves open the role of novel agents pending outcome trials.
Multiple lines of evidence demonstrate that low-density lipoprotein-cholesterol causes atherosclerotic cardiovascular disease. Thus, targeting and lowering low-density lipoprotein-cholesterol is the principal strategy to reduce cardiovascular disease risk in primary and secondary prevention. Statin therapy is the foundation of lipid-lowering treatment, but adherence rates are low, and many individuals do not attain target low-density lipoprotein-cholesterol values. Additionally, most statin-treated patients are still at considerable atherosclerotic cardiovascular disease risk, emphasizing the need for more aggressive low-density lipoprotein-cholesterol-lowering therapies. The purpose of this review is to discuss new and emerging approaches to further lower low-density lipoprotein-cholesterol, including inhibition of ATP-citrate lyase, proprotein convertase subtilisin-kexin type 9, angiopoietin-related protein 3, and cholesteryl ester transfer protein.
No takes yet. Share an insight, caveat, or question.
Rikhi et al. (2022) conducted a review in Atherosclerotic cardiovascular disease. New and emerging LDL-C lowering agents (ATP-citrate lyase, PCSK9, ANGPTL3, and CETP inhibitors) was evaluated. New and emerging LDL-C lowering agents, including inhibitors of ATP-citrate lyase, PCSK9, ANGPTL3, and CETP, offer strategies to address residual ASCVD risk in patients not reaching targets on statins.
Synapse has enriched 10 related papers. Consider them for comparative context: